550 related articles for article (PubMed ID: 21419774)
1. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis.
Sánchez-Burgos G; Ramos-Castañeda J; Cedillo-Rivera R; Dumonteil E
Virus Res; 2010 Oct; 153(1):113-20. PubMed ID: 20638434
[TBL] [Abstract][Full Text] [Related]
3. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
[TBL] [Abstract][Full Text] [Related]
4. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.
Hughes HR; Crill WD; Davis BS; Chang GJ
Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913
[TBL] [Abstract][Full Text] [Related]
5. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
6. Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.
Ramanathan B; Poh CL; Kirk K; McBride WJ; Aaskov J; Grollo L
PLoS One; 2016; 11(5):e0155900. PubMed ID: 27223692
[TBL] [Abstract][Full Text] [Related]
7. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.
Block OK; Rodrigo WW; Quinn M; Jin X; Rose RC; Schlesinger JJ
Vaccine; 2010 Nov; 28(51):8085-94. PubMed ID: 20959154
[TBL] [Abstract][Full Text] [Related]
8. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
[TBL] [Abstract][Full Text] [Related]
9. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy.
Liu K; Jiang D; Zhang L; Yao Z; Chen Z; Yu S; Wang X
Vaccine; 2012 Apr; 30(19):3034-41. PubMed ID: 22008818
[TBL] [Abstract][Full Text] [Related]
10. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
11. An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara.
Quinan BR; Flesch IE; Pinho TM; Coelho FM; Tscharke DC; da Fonseca FG
Vaccine; 2014 May; 32(25):2972-9. PubMed ID: 24726244
[TBL] [Abstract][Full Text] [Related]
12. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
[TBL] [Abstract][Full Text] [Related]
14. Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.
Lim HX; Lim J; Poh CL
Med Microbiol Immunol; 2021 Feb; 210(1):1-11. PubMed ID: 33515283
[TBL] [Abstract][Full Text] [Related]
15. Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs.
Tarradas J; Monsó M; Muñoz M; Rosell R; Fraile L; Frías MT; Domingo M; Andreu D; Sobrino F; Ganges L
Vaccine; 2011 Jun; 29(26):4422-9. PubMed ID: 21496472
[TBL] [Abstract][Full Text] [Related]
16. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
[TBL] [Abstract][Full Text] [Related]
17. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes.
Gangwar RS; Shil P; Sapkal GN; Khan SA; Gore MM
Virus Res; 2012 Jan; 163(1):40-50. PubMed ID: 21889960
[TBL] [Abstract][Full Text] [Related]
18. Identification of B cell epitopes of dengue virus 2 NS3 protein by monoclonal antibody.
Tian Y; Chen W; Yang Y; Xu X; Zhang J; Wang J; Xiao L; Chen Z
Appl Microbiol Biotechnol; 2013 Feb; 97(4):1553-60. PubMed ID: 23081772
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
Roehrig JT; Bolin RA; Kelly RG
Virology; 1998 Jul; 246(2):317-28. PubMed ID: 9657950
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.
Valdés I; Hermida L; Gil L; Lazo L; Castro J; Martín J; Bernardo L; López C; Niebla O; Menéndez T; Romero Y; Sánchez J; Guzmán MG; Guillén G
Int J Infect Dis; 2010 May; 14(5):e377-83. PubMed ID: 19773190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
